Alexion Pharmaceuticals Research Scientist II, IVIVP in New Haven, Connecticut
This position is Essential based in New Haven, CT with the expectation of being onsite on a regular basis
The Research Scientist II will work within the In vitro/In vivo Pharmacology Team to lead or contribute to projects from the Alexion portfolio. T he successful candidate is expected to d evelop of new in vivo models and to execute in vivo, ex vivo and in vitro studies to evaluate new drug targets, novel drug candidates and treatment modalities to address unmet medical needs. The position is primarily bench focused (70%) and collaborative in nature. The successful candidate is expected to drive the publication of data in high quality scientific, technical or medical journals, to represent the department and programs at external meetings, to be a key representative to our collaborators, and to promote collaborative efforts within and outside of Alexion.
Develop and evaluate in vivo and in vitro models and new assays, and build strong internal scientific expertise in the rare disease arena
Independently plan, design, and execute in vitro, ex vivo and in vivo studies; analyze and interpret the data to support novel drug discovery and development efforts
Present research progress and recommendations to project team and senior staff and write study reports and manuscripts.
Contribute to preparation of patent and IND filings
Manage multiple projects simultaneously and work closely with cross-functional team members to advance portfolio programs
Mentor junior scientists/research associates
Manage alliances with CRO’s, industry and academic partners
The scientist will be able to prioritize tasks and coordinate efforts to deliver results under aggressive timelines, keep meticulous records, communicate clearly and concisely (oral and written) internally and externally as well as remaining current on new advances and methodologies.
Demonstrate successful and substantial work with in vivo modeling and manipulations
Solid understanding of immunology , neuroscience is highly desirable
A track record of successfully delivering results on a timeline
Experience in collaborating within a matrix research organization desirable
Ability to drive aggressive timelines
Bibliography consistent with high quality seminal research
A good understanding of the drug development process from lead identification through clinical trials is desirable
Ability to formulate testable hypotheses, design experiments, analyze data, conclusions and plan next steps
Ability to contribute to multiple projects, meet deliverables and prioritize tasks accordingly,
Excellent communication and organizational skills, capacity to multi-task and the ability to work in a fast-paced, team-oriented environment are essential
Ph.D. in Immunology, Neuroscience or related discipline (postdoctoral experience preferred), and 2-5 years of relevant industrial experience, or BS/MS with 10- 15 years’ experience in industry
Some opportunities happen only once in a lifetime - like a job where you have the extraordinary opportunity to change lives. At Alexion, such opportunities arise through our unwavering mission to serve patients and families affected by rare diseases. These patients are our guiding star, and we act with integrity, urgency, and discipline because we know their lives are at stake.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.
As a leading employer in our industry, Alexion is proud to offer a highly competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, 401(k) with company match, tuition reimbursement, relocation assistance and much more.